Table 5.
Comparisons with phase 1–3 prospective trials.
| Frontline Ibrutinib | Ibrutinib as 2nd Line Onward | ||||||
|---|---|---|---|---|---|---|---|
| This Study | Byrd 2020 (4) | Burger 2020 (8) | Farooqui 2015 (10) | This Study | Byrd 2020 (4) | Munir 2019 (6) | |
| N | 10 | 31 | 136 | 35 | 36 | 101 | 195 |
| Median age | 63 | 71 | 73 | 62 | 62 | 64 | 67 |
| TP53 mut | 40% | NA | 10% | 6% | 3% | NA | NA |
| del(17p) | 60% | 6% | 0 (*) | 94% | 14% | 34% | 32% |
| IGHV unmut | 50% | 48% | 43% | 63% | 33% | 78% | NA |
| Best ORR | 90% | 87% | 92% | 70% | 97% | 89% | 91% |
| Best CR rate | 10% | 35% | 30% | 12% | 3% | 10% | 11% |
| Follow-up | 24 mos | 87 mos | 60 mos | 24 mos | 26 mos | 82 mos | 65 mos |
| Median PFS | 29 mos | NR | NR | NR | 21 mos | 52 mos | 44 mos |
| Median OS | NR | NR | NR | NR | 59 mos | 92 mos | 68 mos |
(*) patients with del(17p) were excluded from the trial. CR, complete response; mos, months; NA, not reported in the paper; NR, not reached; ORR, overall response rate; PFS, progression-free survival; OS, overall survival.